ArticleCureus2024
Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia universalis (AU) is a severe form of alopecia areata characterized by the complete loss of scalp and body hair. While Janus kinase (JAK) inhibitors like baricitinib have shown promise in promoting hair regrowth in severe cases of AU, unexpected side effects, such as hair depigmentation, have not been widely reported. We present the case of a young male with AU who experienced progressive and extensive whitening of his scalp and body hair following treatment with baricitinib. After one month of therapy, the patient observed both black and white hairs emerging, which gradually turned entirely white by the second month. Over the course of seven months, the whitening of the hair persisted, with no repigmentation observed. Laboratory tests and clinical evaluations indicated no significant adverse effects, suggesting that baricitinib was well tolerated. Dermoscopic examination revealed predominantly white terminal hairs. While the mechanisms underlying this phenomenon remain unclear, we discuss potential interactions between JAK inhibition and melanocyte function, suggesting that baricitinib's modulation of the JAK-STAT pathway may impact melanogenesis and hair pigmentation. This case highlights the need for further investigation into the effects of JAK inhibitors on hair pigmentation and the potential for hair whitening as an uncommon side effect. Understanding these mechanisms is essential for improving treatment strategies for AU and addressing patient concerns regarding pigmentation changes during therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.